ProKidney to Present at Two Upcoming Healthcare Conferences in September.

ProKidney Corp. announces participation in two upcoming healthcare conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference. Senior management team members will participate in fireside chats on September 3 and September 8, respectively. The live webcasts will be available on ProKidney's website. Investors interested in one-on-one meetings should contact their banking representatives.

ProKidney Corp. (Nasdaq: PROK), a late clinical-stage cellular therapeutics company specializing in chronic kidney disease (CKD), has announced its participation in two major healthcare conferences in September 2025. The company will present at the Citi Biopharma Back to School Conference in Boston on September 3 at 10:30am ET, and the Morgan Stanley Global Healthcare Conference in New York on September 8 at 7:00am ET. Both presentations will be in a fireside chat format and available via webcast through ProKidney's investor relations website.

The live webcasts of the fireside chats will be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website. Investors interested in one-on-one meetings should contact their banking representatives.

ProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. The company's lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy with regenerative medicine advanced therapy designation. It is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes.

For more information, please visit [ProKidney's website](https://www.prokidney.com).

References:
[1] https://www.stocktitan.net/news/PROK/pro-kidney-to-participate-in-two-upcoming-conferences-the-citi-yymbscsr320k.html